[Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
Activation of the endothelin-1 system plays a key role in the pathogenesis of pulmonary arterial hypertension (PAH). The endothelin-1 receptor antagonist bosentan inhibits the action of endothelin-1 at both receptor subtypes (ET(A) and ET(B) receptors) and has been approved for PAH therapy since 2001. Recent data were presented at an international symposium in Barcelona in February 2006.
Musch
Annemarie
A
Redaktion Medizinische Monatsschrift für Pharmazeuten, Birkenwaldstr. 44, 70191 Stuttgart. amusch@deutscher-apothekerverlag.de
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012595:Scleroderma, Systemic / Q000209:etiology / Q000517:prevention & control; D013449:Sulfonamides / Q000627:therapeutic use*
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D000077300:Bosentan